BiomX (PHGE) Total Liabilities (2018 - 2026)
BiomX's (PHGE) quarterly Total Liabilities came in at $10.6 million in Q2 2026, down 44.08% year-over-year from $18.9 million in Q2 2025, and up 155.64% quarter-over-quarter from $4.1 million in Q1 2026.
Analysis
BiomX (PHGE) Total Liabilities (2018 - 2026) Analysis & Trends
BiomX has disclosed Total Liabilities across 9 years of filings, most recently posting $10.6 million for Q2 2026.
- In Q2 2026, Total Liabilities fell 44.08% year-over-year to $10.6 million; the TTM figure through Jun 2026 stood at $10.6 million (down 44.08% YoY), while the FY2025 annual figure was $7.1 million, down 62.88% from the prior year.
- Total Liabilities came in at $10.6 million for Q2 2026 at BiomX, up from $4.1 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $41.2 million in Q2 2024 to a low of $203000.0 in Q4 2022.
- Average Total Liabilities over 5 years is $18.1 million, with a median of $20.1 million recorded in 2024.
- Year-over-year, Total Liabilities slumped 99.33% in 2022 and jumped 10711.82% in 2023.
- Over 5 years, Total Liabilities stood at $203000.0 in 2022, then jumped by 10711.82% to $21.9 million in 2023, then dropped by 13.04% to $19.1 million in 2024, then plunged by 62.88% to $7.1 million in 2025, then soared by 49.09% to $10.6 million in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $10.6 million in Q2 2026, $4.1 million in Q1 2026, and $7.1 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 83.95 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 37.53 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 7.18 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 10.02 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 1.62 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 4.20 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 13.24 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 1.35 Bn |
| 10 | BiomX | 1.55 Mn | 7.73 Mn | 97,000.00 | 10.56 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.56 Mn |
| Mar 31, 2026 | 4.13 Mn |
| Dec 31, 2025 | 7.09 Mn |
| Sep 30, 2025 | 15.68 Mn |
| Jun 30, 2025 | 18.89 Mn |
| Mar 31, 2025 | 21.16 Mn |
| Dec 31, 2024 | 19.09 Mn |
| Sep 30, 2024 | 22.08 Mn |
| Jun 30, 2024 | 41.19 Mn |
| Mar 15, 2024 | 14.08 Mn |
| Dec 31, 2023 | 21.95 Mn |
| Sep 30, 2023 | 24.90 Mn |
| Jun 30, 2023 | 25.39 Mn |
| Mar 31, 2023 | 247,000.00 |
| Dec 31, 2022 | 203,000.00 |
| Sep 30, 2022 | 25.34 Mn |
| Jun 30, 2022 | 25.64 Mn |
| Mar 31, 2022 | 28.73 Mn |
| Dec 31, 2021 | 30.46 Mn |
| Sep 30, 2021 | 28.37 Mn |